Related Experiment Video
Updated: Jul 20, 2026
Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes
Published on: September 24, 2013
Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex
R D Cohn1, M Durbeej, S A Moore
1Howard Hughes Medical Institute, Department of Physiology and Biophysics, Department of Neurology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
Abstract:
Cardiomyopathy is a multifactorial disease, and the dystrophin-glycoprotein complex has been implicated in the pathogenesis of both hereditary and acquired forms of the disease. Using mouse models of cardiomyopathy made by ablating genes for components of the sarcoglycan complex, we show that long-term treatment with verapamil, a calcium channel blocker with vasodilator properties, can alleviate the severe cardiomyopathic phenotype, restoring normal serum levels for cardiac troponin I and normal cardiac muscle morphology. Interruption of verapamil treatment leads again to vascular dysfunction and acute myocardial necrosis, indicating that predilection for cardiomyopathy is a continuing process. In contrast, verapamil did not prevent cardiac muscle pathology in dystrophin-deficient mdx mice, which neither show a disruption of the sarcoglycan complex in vascular smooth muscle nor vascular dysfunction. Hence, our data strongly suggest that pharmacological intervention with verapamil merits investigation as a potential therapeutic option not only for patients with sarcoglycan mutations, but also for patients with idiopathic cardiomyopathy associated with myocardial ischemia not related to atherosclerotic coronary artery disease.
Insights
Verapamil treatment improved cardiomyopathy in mouse models with sarcoglycan gene defects. This suggests verapamil may be a potential therapy for certain cardiomyopathies, especially those involving vascular dysfunction.
Area of Science:
- Biomedical Research
- Cardiovascular Science
- Pharmacology
Background:
- Cardiomyopathy is a complex heart muscle disease.
- The dystrophin-glycoprotein complex plays a role in hereditary and acquired cardiomyopathies.
- Sarcoglycan gene mutations are linked to severe cardiomyopathy.
Purpose of the Study:
- To investigate the therapeutic potential of verapamil in mouse models of cardiomyopathy.
- To determine if verapamil can alleviate cardiomyopathy associated with sarcoglycan complex disruption.
- To explore verapamil's efficacy in models with and without sarcoglycan complex vascular involvement.
Main Methods:
- Utilized mouse models with genetic ablation of sarcoglycan complex components.
- Administered long-term verapamil treatment, a calcium channel blocker.
- Assessed cardiac troponin I levels, cardiac muscle morphology, and vascular function.
- Compared verapamil's effects in sarcoglycan-deficient mice versus dystrophin-deficient (mdx) mice.
Main Results:
- Long-term verapamil treatment alleviated severe cardiomyopathy in sarcoglycan-deficient mice.
- Verapamil restored normal cardiac troponin I levels and cardiac muscle morphology.
- Cessation of verapamil led to recurrent vascular dysfunction and myocardial necrosis.
- Verapamil did not prevent cardiac pathology in mdx mice lacking sarcoglycan complex vascular disruption.
Conclusions:
- Pharmacological intervention with verapamil shows promise for treating sarcoglycan-related cardiomyopathies.
- Verapamil may be a viable therapeutic option for idiopathic cardiomyopathy with myocardial ischemia.
- The findings highlight the critical role of sarcoglycan complex integrity in vascular smooth muscle function and cardiomyopathy prevention.
